全文获取类型
收费全文 | 249434篇 |
免费 | 19669篇 |
国内免费 | 7285篇 |
专业分类
耳鼻咽喉 | 1804篇 |
儿科学 | 9393篇 |
妇产科学 | 2387篇 |
基础医学 | 22838篇 |
口腔科学 | 4456篇 |
临床医学 | 25875篇 |
内科学 | 60365篇 |
皮肤病学 | 3328篇 |
神经病学 | 29083篇 |
特种医学 | 6996篇 |
外国民族医学 | 12篇 |
外科学 | 20474篇 |
综合类 | 31954篇 |
现状与发展 | 33篇 |
一般理论 | 11篇 |
预防医学 | 19634篇 |
眼科学 | 3206篇 |
药学 | 17777篇 |
192篇 | |
中国医学 | 11219篇 |
肿瘤学 | 5351篇 |
出版年
2024年 | 232篇 |
2023年 | 4841篇 |
2022年 | 6536篇 |
2021年 | 12255篇 |
2020年 | 12180篇 |
2019年 | 10587篇 |
2018年 | 10313篇 |
2017年 | 9525篇 |
2016年 | 9451篇 |
2015年 | 9295篇 |
2014年 | 17913篇 |
2013年 | 20071篇 |
2012年 | 14715篇 |
2011年 | 16138篇 |
2010年 | 12406篇 |
2009年 | 11833篇 |
2008年 | 11765篇 |
2007年 | 11085篇 |
2006年 | 9740篇 |
2005年 | 8139篇 |
2004年 | 7012篇 |
2003年 | 6029篇 |
2002年 | 5024篇 |
2001年 | 4372篇 |
2000年 | 3727篇 |
1999年 | 3040篇 |
1998年 | 2629篇 |
1997年 | 2279篇 |
1996年 | 1987篇 |
1995年 | 2092篇 |
1994年 | 1942篇 |
1993年 | 1642篇 |
1992年 | 1533篇 |
1991年 | 1386篇 |
1990年 | 1108篇 |
1989年 | 941篇 |
1988年 | 877篇 |
1987年 | 799篇 |
1986年 | 684篇 |
1985年 | 1266篇 |
1984年 | 1231篇 |
1983年 | 813篇 |
1982年 | 941篇 |
1981年 | 797篇 |
1980年 | 636篇 |
1979年 | 573篇 |
1978年 | 469篇 |
1977年 | 381篇 |
1976年 | 347篇 |
1975年 | 275篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
《Vaccine》2022,40(43):6201-6205
Systemic immunosuppressive therapy (IS) renders patients with inflammatory bowel disease (IBD) vulnerable to fulminant hepatitis B virus (HBV) infection. Seroprotection against HBV through a full vaccination scheme is preferably obtained before IS is initiated, but often conflicts with the clinical need to initiate therapy rapidly. Consequently, the vast majority of patients will use IS during booster vaccinations. In this retrospective cohort study, we examined the serological response after a modified vaccination schedule which includes an initial double dose of Fendrix in patients with IBD and compared the results with the serological responses of patients with IBD who received the standard schedule. Seroprotection rates were 86.2 % and 88.9 % in the modified and standard schedule groups respectively. One-third of patients obtained seroprotection after only one double dose vaccine. A double dose may be considered in patients with IBD at high short-term risk of HBV infection when a rapid protective response is warranted. 相似文献
82.
川崎病(Kawasaki disease,KD)是一种急性自身免疫性系统性血管炎,是发达国家儿童获得性心脏病的主要病因。KD最严重的后果是冠状动脉病变(coronary artery lesions,CALs),与KD的预后相关。临床研究证实静脉注射丙种球蛋白(IVIG)耐药是CALs的独立危险因素。近年来,一系列的预测模型已被开发来评估IVIG耐药的风险。然而,目前基于KD儿童人口学特征、临床表现、实验室检查及遗传特性的IVIG耐药性预测评分系统在不同民族和同一民族不同地区的人群中存在显著差异,尚未建立适用普遍人群的预测模型。 相似文献
83.
84.
《Saudi Dental Journal》2022,34(7):596-603
ObjectiveStudies have shown that gingival crevices may be a significant route for SARS-CoV-2 entry. However, the role of oral health in the acquisition and severity of COVID-19 is not known.DesignA retrospective analysis was performed using electronic health record data from a large urban academic medical center between 12/1/2019 and 8/24/2020. A total of 387 COVID-19 positive cases were identified and matched 1:1 by age, sex, and race to 387 controls without COVID-19 diagnoses. Demographics, number of missing teeth and alveolar crestal height were determined from radiographs and medical/dental charts. In a subgroup of 107 cases and controls, we also examined the rate of change in alveolar crestal height. A conditional logistic regression model was utilized to assess association between alveolar crestal height and missing teeth with COVID-19 status and with hospitalization status among COVID-19 cases.ResultsIncreased alveolar bone loss, OR = 4.302 (2.510 – 7.376), fewer missing teeth, OR = 0.897 (0.835–0.965) and lack of smoking history distinguished COVID-19 cases from controls. After adjusting for time between examinations, cases with COVID-19 had greater alveolar bone loss compared to controls (0.641 ± 0.613 mm vs 0.260 ± 0.631 mm, p < 0.01.) Among cases with COVID-19, increased number of missing teeth OR = 2.1871 (1.146– 4.174) was significantly associated with hospitalization.ConclusionsAlveolar bone loss and missing teeth are positively associated with the acquisition and severity of COVID-19 disease, respectively. 相似文献
85.
86.
87.
认知障碍是指记忆、语言、理解和判断等一个或多个方面的功能障碍,包括轻度认知障碍和各种类型的痴呆症。痴呆症是认知障碍最严重的表现,是一种导致患者日常生活、社会交往和工作能力发生显著变化的综合征。阿尔茨海默病(AD)是最常见的痴呆症类型,其次是血管性痴呆(VD)和其他神经退行性痴呆[1]。已知年龄与认知功能的退化密切相关。 相似文献
88.
89.
【目的】 在“中国科技期刊卓越行动计划”实施三周年之际,有必要对我国科技期刊2035年迈入“世界第一方阵”目标的具体任务进行重新审视和预判,以进一步明确发展方向,动态调整推进思路。【方法】 采用国内外科技期刊、科技论文、科技期刊评价成果的系统性发展数据对科技期刊“世界第一方阵” 国家(或地区)在高水平科技期刊数量与质量层面的入围标准进行界定,在深入总结现有基础和优势的同时,对我国科技期刊综合实力与“世界第一方阵”国家(或地区)的现实差距进行逐一梳理和剖析,并对实现目标的可行性和推进思路进行研判和设计。【结果】 必须继续加强高水平英文科技期刊创办和培育力度、持续加大优秀中文科技期刊的建设强度、快速推进国内外科技期刊论文等质同效评价制度的建设与引导,并积极探索建立科学家和科研机构办好一流科技期刊的责任制度和贡献激励机制、创新发展编辑人才队伍培养与激励管理思路、深入实践灵活多样的期刊出版市场资本运作模式、稳步推进期刊出版市场机制和管理制度改革,为我国科技期刊事业的高质量发展提速增效。【结论】 虽然当前阶段目标任务艰巨,但迈入“世界第一方阵”未来可期。 相似文献
90.
《Vaccine》2022,40(24):3380-3388
BackgroundWe evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants.MethodsThis phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments. Participants were stratified by age (< 65 or ≥ 65 years) and randomized to receive two doses of either NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1) or placebo, 21 days apart. Primary outcomes were safety and immunogenicity assessed by serum IgG antibody levels against SARS-CoV-2 rS protein on day 36. Herein, we report the primary data analysis at 4 weeks after the second dose, ahead of 12-month follow-up completion (data cut-off: 8 May 2021).ResultsBetween 12 February 2021 and 17 March 2021, 326 subjects were screened, and 200 participants enrolled and randomized: NVX-CoV2373, n = 150; placebo, n = 50. Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. In the NVX-CoV2373 arm, tenderness and injection site pain were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with NVX-CoV2373 (n = 150) by day 36: IgG geometric mean fold rise (95% confidence interval) 259 (219, 306); seroconversion rate 100% (97.6, 100). No such response occurred with placebo (n = 49).ConclusionTwo doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults. Funding: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). ClinicalTrials.gov identifier: NCT04712110. 相似文献